focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksActiveops Regulatory News (AOM)

Share Price Information for Activeops (AOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 100.50
Bid: 100.00
Ask: 101.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.00%)
Open: 100.50
High: 100.50
Low: 100.50
Prev. Close: 100.50
AOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Full Year Trading Update and Notice of Results

24 Apr 2024 07:00

RNS Number : 7681L
ActiveOps PLC
24 April 2024
 

24 April 2024 

 

ActiveOps plc 

("ActiveOps", the "Company" or the "Group") 

 

Full Year Trading Update

and Notice of Results

 

ActiveOps plc (AIM: AOM), a leading provider of Decision Intelligence software for service operations, is pleased to provide an update on trading for the year ended 31 March 2024. Highlights include good growth in adjusted EBITDA*, profit before tax and cash, with an 11% increase in SaaS revenue on a constant currency ("CC") basis and exit Annual Recurring Revenue ("ARR") up by 14% CC versus the prior year.

FY24 Financial highlights

Group revenue is expected to be approximately £26.8m, an increase of 5% on the prior year (FY 2023: £25.5m) or approximately 9% on a CC basis, reflecting a healthy SaaS performance alongside an ongoing challenging backdrop for training and implementation services, as seen in H1.

The Group has seen strong growth in adjusted EBITDA which is expected to be at least £2.2m (FY 2023: £0.7m), including an increase in capitalised R&D spend of approximately £0.5m to £1.35m (FY 2023 £0.85m, capitalised), as the Group continues to focus on the development of advanced AI-based product features. In addition, prudent cost management has offset the impact of some adverse FX movement. Building on the positive profit before tax performance seen in H1, the Group expects to report continued strong growth in profit before tax for the full year.

Cash generation has been strong, resulting in an increased year-end cash position of £17.6m (FY 2023: £15.4m).

SaaS revenues increased by approximately 8% on the prior year (11% on a CC basis). This, coupled with strong Net Revenue Retention of 110% on a CC basis has seen Annual Recurring Revenue increase to approximately £25.1m, an increase of approximately 11% on the prior year (FY 2023: £22.6m) or around 14% on a CC basis, providing a solid exit run rate for the year ahead.

FY24 Operational Highlights and Outlook

Operationally the Group has made good progress, securing new customer wins, strong customer retention and encouraging expansion within the existing customer base. The Group is successfully migrating customers onto ControliQ Series 3 and momentum in CaseworkiQ continues to build, with total CaseworkiQ ARR growth in the year of 95%. Following additional investment in marketing, the Company is seeing an increase in good-quality leads.

Of note in the year has been the winning of three significant ControliQ enterprise contracts following thorough and competitive RfP processes. The proven enterprise-scale capabilities of ControliQ and ability to deliver material cost savings with rapid ROI, as well as ActiveOps' wider product set, exciting AI and ML supported product roadmap, were instrumental to ActiveOps being selected.  

The Group remains well capitalised, and the strength of the balance sheet, the strong market response to the Group's product roadmap and growing number of well qualified sales leads, give the Board confidence to invest in the global sales operation in the coming year, with a view to driving the Group's organic growth rate.

As part of this focus on growth, the Company has recently expanded its Senior Leadership Team through the appointment of a Group Managing Director, APAC Regional Managing Director, and Regional Chair, Africa business, as announced on 25 March 2024. Each individual brings valuable experience and will provide increased focus on the execution of ActiveOps' growth strategy, as the Company looks to build on the strong foundations established since IPO across its key global markets. 

ActiveOps CEO, Richard Jeffery commented: "FY 2024 has seen another solid year for ActiveOps, expanding our customer base while launching exciting innovations within our offerings. Having achieved continued progress in profitability and with a strong balance sheet, we are well placed to invest in the management structure and sales teams to drive further organic growth across all our key markets. We are excited by the uptake of ControliQ Series 3 and the forthcoming release of Series 4, which with AI and ML technologies at their core are primed to make a real difference for our customers and create more value from their service operations. With a strong leadership team in place and market leading offering, we look forward to the year ahead with confidence."

 

Notice of Results

 

The Company intends to announce its results for the year ended 31 March 2024 on 25 June 2024.

 

* Adjusted EBITDA is used by management to assess the trading performance of the business. Defined as Operating profit before depreciation, amortisation, share-based payment charges and exceptional items and includes FX differences.

 

** Company compiled range is based on known sell-side analyst estimates. The latest known sell-side analyst estimates for the full year ended 31 March 2024 are:

 

· Revenue in the range of £27.3m to £27.4m

· Adjusted EBITDA in the range of £1.0m to £1.3m

· Adjusted PBT in the range of £0.4m to £0.7m

· Cash in the range of £15.6m to £17.2m

 

 

For more information, please contact:

 

ActiveOps

Via Alma

Richard Jeffery, Chief Executive Officer

www.activeops.com

Emma Salthouse, Chief Financial Officer

 

Investec Bank plc

+44 (0)20 7597 5970

Corporate Broking & PLC Advisory

Patrick Robb / Nick Prowting

 

Alma Strategic Communications

+ 44(0) 203 405 0205

Caroline Forde / Will Ellis Hancock

 

About ActiveOps

The Company's offerings provide predictive and prescriptive insight to help service operations make better decisions - faster. The Company's AI-powered SaaS solutions are underpinned by 15+ years of operational data and its AOM methodology that's proven to drive cross department decision-making. 

With Decision Intelligence, ActiveOps' customers deliver MORE - release 20%+ capacity within the first 12 months and boost productivity by 30%+ leading to MORE business impact. Customer turnaround times are improved substantially, costs are reduced, SLAs are met, and employees are happier and more engaged.

The Company has over 170 employees, serving a global customer base of over 80 enterprise customers from offices in the UK, Ireland, USA, Canada, Australia, India and South Africa. The Group's customers are predominantly in the banking, insurance, healthcare administration and business process outsourcing (BPO) sectors, including Nationwide, TD Bank, Elevance and DXC Technology.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTEAPLDADLLEFA
12
Date   Source Headline
24th Apr 20247:00 amRNSFull Year Trading Update and Notice of Results
19th Apr 20247:00 amRNSDirector/PDMR Dealing
17th Apr 20244:30 pmRNSHolding(s) in Company
3rd Apr 202410:52 amRNSGrant of Options
25th Mar 20247:00 amRNSSenior Leadership Team Appointments
18th Mar 20245:49 pmRNSDirector/PDMR Dealing
26th Feb 20245:58 pmRNSDirector/PDMR Dealing
20th Feb 202412:02 pmRNSDirector/PDMR Dealing
20th Feb 20247:15 amRNSHolding(s) in Company
30th Jan 202410:49 amRNSDirector/PDMR Dealing
19th Jan 20241:00 pmRNSDirector/PDMR Dealing
28th Dec 20233:32 pmRNSDirector/PDMR Dealing
19th Dec 202312:12 pmRNSDirector/PDMR Dealing
7th Dec 20237:00 amRNSHolding(s) in Company
5th Dec 20237:00 amRNSBoard Succession Planning
27th Nov 20234:20 pmRNSDirector/PDMR Dealing
21st Nov 20233:55 pmRNSDirector/PDMR Dealing
14th Nov 20237:00 amRNSInterim Results
10th Nov 20237:00 amRNSNotice of Investor Presentation
8th Nov 20234:29 pmRNSDirector/PDMR Dealing
18th Oct 20234:59 pmRNSDirector/PDMR Dealing
18th Oct 20237:00 amRNSTrading Update and Notice of Half Year Results
28th Sep 202312:48 pmRNSResult of AGM
26th Sep 202311:52 amRNSDirector/PDMR Dealing
26th Sep 20237:00 amRNSLaunch of ControliQ Series 3
18th Sep 20233:01 pmRNSDirector/PDMR Dealing
5th Sep 20237:00 amRNSAppointment of Chief Financial Officer
24th Aug 20232:31 pmRNSDirector/PDMR Dealing
23rd Aug 20235:58 pmRNSPublication of Annual Report and Notice of AGM
18th Aug 20234:59 pmRNSDirector/PDMR Dealing
27th Jul 20231:54 pmRNSHolding(s) in Company
26th Jul 20232:16 pmRNSHolding(s) in Company
25th Jul 20237:00 amRNSDirector/PDMR Dealing
18th Jul 20233:46 pmRNSDirector/PDMR Dealing
4th Jul 20237:00 amRNSResults for the year ended 31 March 2023
28th Jun 20234:36 pmRNSDirector/PDMR Dealing
26th Jun 20237:00 amRNSNotice of Results and Investor Presentation
19th Jun 20233:13 pmRNSDirector/PDMR Dealing
25th May 202311:20 amRNSDirector/PDMR Dealing
19th May 20231:14 pmRNSDirector/PDMR Dealing
25th Apr 20237:00 amRNSFull Year Trading Update
24th Apr 20234:41 pmRNSDirector/PDMR Dealing
21st Apr 202311:45 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSAppointment of new Chief Financial Officer
27th Mar 20231:14 pmRNSDirector/PDMR Dealing
21st Mar 20237:00 amRNSDirector/PDMR Dealing
27th Feb 20237:00 amRNSDirector/PDMR Dealing
20th Feb 202310:38 amRNSDirector/PDMR Dealing
24th Jan 20231:27 pmRNSDirector/PDMR Dealing
18th Jan 202311:18 amRNSDirector/PDMR Dealing
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.